AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL EBITDA Margin
EBITDA as a percentage of revenue.
AVITA Medical, Inc.NASDAQ: RCEL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -44.5%
EBITDA Margin was -44.5% in Q1 FY2026, up 20.8 pp from a year earlier. On a trailing-twelve-month basis it was -52.1%, up 18.1 pp year over year. Over 3 fiscal years it widened by 20.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -21.2% for the fiscal year ending Dec 2026, up from -55.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -44.5%+10.6 pp QoQ
- Last fiscal yearDec 2025
- -55.3%+30.8 pp YoY
- LTMMar 2026
- -52.1%+18.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.8 pp | +9.6 pp | -11.2 pp |
| 1 year | +30.8 pp | +34.1 pp | +3.3 pp |
| 3 years | +20.4 pp | +61.1 pp | +40.7 pp |
| 5 years | +83.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -55.3%
- Year-over-year change
- +30.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -55.3% | +30.8pp |
| FY2024 | 2024-12-31 | -86.1% | -19.2pp |
| FY2023 | 2023-12-31 | -66.9% | +8.8pp |
| FY2022 | 2022-12-31 | -75.7% | -1.8pp |
| FY2021 | 2021-12-31 | -73.9% | — |
EBITDA Margin vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 EBITDA Margin of -52.1% is the 4th highest of the 8 companies compared; the peer median is -216.2%.
- Its year-over-year change of +18.1 pp is the 5th highest of 8, against a peer median of +24.0 pp.
- Over three fiscal years its change of +20.4 pp compares with a peer median of +812.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.1% | -3.2 pp | -10.6 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -216.2% | +118.9 pp | +812.8 pp | |
| LTM Mar 2026 | -337.0% | +4411.9 pp | +3368.5 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
| LTM Mar 2026 | -4623.1% | -3172.4 pp | +10652.3 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding RCEL) | -216.2% | +24.0 pp | +812.8 pp | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.